For years, mammalian cells and microbial systems have dominated the biotech landscape, shaping the economics and access to life-saving biologics. Yet, in countries where capital and infrastructure are limited, those gold-standard systems bring hefty price tags and daunting complexity. The answer isn't bigger bioreactors; it's alternative biomanufacturing approaches, such as molecular farming. Imagine medicines grown like crops, ready for harvest in days, not months.

Meet Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, a scientist who didn't settle for the status quo. As the driving force behind the company, she led the charge to cut through process bottlenecks: navigating regulatory hurdles, scaling plant-based vaccine manufacturing to 5 million doses per month, and reshaping the approach to antibody production for oncology and infectious diseases. Her work proved that plants aren't an alternative. They're a platform.

Topics discussed include:

• How plant-based molecular farming compares to traditional microbial and mammalian cell systems (02:44)
• The flexibility and rapid scalability of using plants for biomanufacturing (05:06)
• Speeding up process development with transient expression versus transgenic plants (05:45)
• Regulatory perspectives and the approval process for plant-produced biologics (06:52)
• An overview of the ongoing oncology and infectious disease antibody pipeline (08:08)
• Strategic challenges: balancing product development, revenue, and market-ready innovations through subsidiary companies (09:51)
• Lessons learned from building a GMP facility capable of 5 million doses per month during the pandemic, with supply chain as the biggest bottleneck (12:50)
• Future innovations in molecular farming and the role of plant platforms in medicine production (14:47)

Smart insight:

Platform choice matters. If you're struggling with long development timelines or scale-up challenges, it may not always be the molecule. It may be the system you're using. Molecular farming offers a different set of trade-offs: faster development, flexible scaling, and a practical alternative worth considering before defaulting to a single platform.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:

• Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
• Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
• Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran

Connect with Waranyoo Phoolcharoen:

Email: Waranyoo.P@baiyaphytopharm.com

Baiya Phytopharm website: www.baiyaphytopharm.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show